Q32 Bio (Q32 Bio) Long-Term Capital Lease Obligation : $6.10 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Long-Term Capital Lease Obligation?

Q32 Bio's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.10 Mil.

Q32 Bio's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($6.39 Mil) to Dec. 2023 ($6.25 Mil) and declined from Dec. 2023 ($6.25 Mil) to Mar. 2024 ($6.10 Mil).

Q32 Bio's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($6.79 Mil) but then declined from Dec. 2022 ($6.79 Mil) to Dec. 2023 ($6.25 Mil).

Q32 Bio Long-Term Capital Lease Obligation Historical Data

The historical data trend for Q32 Bio's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Long-Term Capital Lease Obligation Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

6.79

6.25

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			6.79	-	6.39	6.25	6.10

Q32 Bio (NAS:QTTB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Q32 Bio Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024